Crossmark

Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial

Crossref DOI link: https://doi.org/10.1186/s12885-025-14234-5

Published Online: 2025-05-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lan, Tianhang

Zhu, Yingying

Zhong, Wenlong

Tan, Qihong

Lin, Tianxin

Huang, Jian

He, Wang
License Information

Text and Data Mining valid from 2025-05-13

Version of Record valid from 2025-05-13
More Information

Article History

Received: 4 June 2024

Accepted: 28 April 2025

First Online: 13 May 2025

Declarations

:

: The study protocol was approved by Medical Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Written informed consent will be obtained from all objects prior to enrollment. Participants will be made aware that participation is strictly voluntary. Participants may withdraw from the study at any time.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below